dotMD.com
Join Community
📖Clinical Research Library Talk in GLP-1s, Weight & Muscle Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare GLP-1 titration schedules, nausea fixes, and protein routines—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to GLP-1s, Weight & Muscle Space (15 Seconds • No Account or Email Required)
Or read existing discussions in GLP-1s, Weight & Muscle Space →
★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,255 Indexed Studies

GLP-1s, Diabetes, Blood Sugar & Metabolic Trials — Clinical Trial Breakdowns & PubMed Evidence

Phase 3 outcomes from NEJM SURMOUNT-1, SURPASS-2, STEP-1, and Lancet Orforglipron oral GLP-1 trials—plus hepatic dawn phenomenon physiology, 15-minute post-meal GLUT4 walks, and first-30-day Type 2 Diabetes remission protocols. Explore 698 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Read the Full Breakthrough Breakdown → Jump to All 15 Landmark Breakthroughs ↓
Two biomedical scientists in white lab coats inside a sunlit medical research laboratory pipetting clinical assay samples and reviewing trial results
Inside the Clinical Evidence Lab: Our research desk audits 6,255 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.
Reset
1. Major Clinical Breakthroughs & Deep-Dive Study Breakdowns (5 Guides)

GLP-1s, Diabetes & Blood Sugar: Landmark Study Breakdowns

Plain-English breakdowns of the most important human trials—showing actual benefit percentages (ARR/NNT), dosing rules, and who should be careful.

24-Hour Continuous Glucose Monitoring (CGM) Study N = 248 Non-Insulin T2D Patients

Why Is My Blood Sugar High in the Morning—Even When I Didn’t Eat Breakfast? (The Dawn Phenomenon Explained)

Bottom-Line Trial Result: Morning Glucose Surge: +20 to +45 mg/dL Between 3:00 AM and 8:00 AM • Adds +0.4% to Overall HbA1c (p < 0.001)

Waking up to a 145 or 165 mg/dL fasting reading after an early, healthy dinner feels deeply frustrating. Continuous glucose monitoring (CGM) studies show that in 55% of Type 2 diabetes patients, a 3:00 A.M. to 8:00 A.M. surge of growth hormone and cortisol triggers the liver to dump stored sugar (+20 mg/dL fasting glucose and +0.4% HbA1c). Here is how to tell the Dawn Phenomenon apart from the Somogyi rebound—and 4 evening adjustments that calm it down.

Condition: Type 2 Diabetes Rx: Metformin ER
7 Min Read • ~1,250 Words Read Study Guide →
Randomized Crossover CGM Exercise Timing Trials N = 840 Participants Across 3 Crossover Trials

The 15-Minute After-Dinner Walk That Cuts Blood Sugar Spikes by 22% to 30%—Without Needing Extra Insulin

Bottom-Line Trial Result: Post-Dinner Glucose iAUC: -22% to -30% With a 10–15 Min Walk vs. Sitting (p < 0.001) • Beats a Single 45-Min Morning Walk

Why sitting on the couch right after dinner traps glucose in your bloodstream—and how a relaxed 10-to-15-minute neighborhood stroll opens a mechanical "side door" (contraction-mediated GLUT4 translocation) in your leg muscles right as meal carbohydrates peak.

Condition: Type 2 Diabetes Condition: Prediabetes
7 Min Read • ~1,250 Words Read Study Guide →
DiRECT Cluster-Randomized Trial & ADA Standards of Care N = 298 DiRECT RCT + ADA Guideline Cohort

Just Told You Have Type 2 Diabetes? Take a Breath—Here Is Your Calm, Evidence-Audited First-30-Days Clinical Plan

Bottom-Line Trial Result: Drug-Free T2D Remission (<6.5% HbA1c): 46% Overall (vs. 4% control, ARR: 42%, p < 0.0001) • 86% Remission With >=15 kg Loss

Seeing an HbA1c of 6.5% or higher on your lab portal can feel like a punch to the stomach. You do not have to throw out your pantry tonight or starve yourself tomorrow. Here is a calm, week-by-week First-30-Days plan grounded in American Diabetes Association (ADA) Standards of Care, the Lancet DiRECT remission trial, and stomach-safe Extended-Release Metformin rules.

Condition: Type 2 Diabetes Rx: Metformin ER
8 Min Read • ~1,300 Words Read Study Guide →
NEJM 3-Year Phase 3 RCT (SURMOUNT-1) N = 1,032 Adults (176 Weeks)

NEJM 3-Year SURMOUNT-1 Study: Once-Weekly Tirzepatide Cuts Progression From Prediabetes to Type 2 Diabetes by 94%

Bottom-Line Trial Result: ARR: 11.4% (1.2% vs. 12.6% placebo) • RRR: 94% (HR 0.06, p < 0.001) • NNT = 9 • -22.9% Body Weight

In a landmark 176-week randomized double-blind trial published in the New England Journal of Medicine (N = 1,032 adults with prediabetes and obesity), once-weekly tirzepatide (Mounjaro / Zepbound) reduced progression to Type 2 diabetes by 94% (1.2% vs. 12.6% placebo, HR 0.06, p < 0.001) while sustaining up to 19.7% weight loss. Here are the exact numbers, the 17-week off-treatment rebound data, and what it means for real patients.

Rx: Tirzepatide Condition: Type 2 Diabetes
8 Min Read • ~1,300 Words Read Study Guide →
NEJM & Lancet Oral GLP-1 Trials N = 831 Adults (36–40 Weeks)

Once-Daily Oral GLP-1 Pill (Orforglipron) Cuts Body Weight by Up to 14.7% Without Fasting Rules: Inside the NEJM & Lancet Trials

Bottom-Line Trial Result: Weight Change: -14.7% vs. -2.3% placebo (Net -12.4%, p < 0.001) • HbA1c -1.8% • Zero Food/Water Fasting Restriction

Unlike weekly GLP-1 injections (Ozempic, Wegovy, Zepbound) or peptide pills that require strict morning fasting (Rybelsus), orforglipron is a small-molecule non-peptide GLP-1 receptor agonist that can be swallowed at any time of day with or without food. Across NEJM and Lancet randomized trials (PMID: 37351564, PMID: 37351565, PMID: 41275875), once-daily orforglipron reduced body weight by up to 14.7% at 36 weeks and lowered HbA1c by -2.10 percentage points.

Rx: Semaglutide Rx: Tirzepatide
8 Min Read • ~1,290 Words Read Study Guide →
3. All Indexed Clinical Studies (698)

GLP-1s, Diabetes & Blood Sugar — Clinical Trials & Study Reports (698)

Page 1 of 24 • Sorted by Participant Sample Size (N)
Randomized Controlled Trial N = 2,859

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

From June 5, 2023, to Feb 15, 2024, 2859 participants were screened, and 1613 (757 [46&#xb7;9%] female) were randomly assigned, following a dose-escalation phase, to receive orforglipron 6 mg (n=329), 12 mg (n=332), 36 mg (n=322), or placebo (n=630), as an adjunct to lifestyle mo

Lancet • 2026-11-06 Read Study
Randomized Controlled Trial N = 2,047

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Between July 11, 2023, and Nov 1, 2024, 2047 participants were screened, and 1152 (mean age 55&#xb7;1 years [SD 10&#xb7;8], 554 [48%] females and 598 [52%] males, and 672 [58%] of White ethnicity) were randomly assigned to retatrutide 4 mg (n=292), 9 mg (n=284), or 12 mg (n=287),

Lancet • 2026-11-06 Read Study
Phase III Randomized Trial N = 212

Phase III Randomized Trial: Targeting Accelerated Aging in COPD: The AMICO (A Trial of Metformin In COpd) Trial Design (N = 212)

AMICO is the first randomized trial specifically designed to evaluate metformin as a gerotherapeutic and disease-modifying intervention in COPD. The study may provide novel evidence supporting geroscience-based approaches to slow disease progression and improve long-term outcomes in patients with COPD.

COPD • 2026-12-15 Read Study
4. Quick Guide • Never Get Fooled by a Headline Again

How to Read a Clinical Study in 30 Seconds

Read FDA Bioequivalence Guide →
1. Relative Risk (RRR) vs. Absolute Risk (ARR)

If a drug drops heart attack risk from 2.0% to 1.0%, headlines scream “50% Relative Risk Reduction!” The real Absolute Risk Reduction (ARR) is 1.0%—meaning 100 people must take the drug (NNT = 100) to prevent 1 event.

2. Double-Blind RCT vs. Observational Association

Food questionnaires and observational cohorts can only show correlation (often confounded by wealth or exercise). Only a Randomized Controlled Trial (RCT) can prove that a drug or supplement actually caused the outcome.

3. Statistical p-Value vs. Clinical Meaning

In a massive 10,000-person trial, a blood pressure drop of 0.8 mmHg can achieve p < 0.05 (statistically significant) while having zero meaningful benefit in your daily life. Always look at the actual effect size.

4. Surrogate Lab Markers vs. Hard Outcomes

Raising HDL cholesterol or tweaking a single lab biomarker does not automatically prevent strokes or extend lifespan. Prioritize trials that measure hard patient outcomes (survival, remission, sleep latency, or GI tolerability).

Evidence Methodology, PubMed Verification & YMYL Standards

Frequently Asked Questions About dotMD Clinical Trial Breakdowns

Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.